RSS-Feed abonnieren
DOI: 10.1055/s-0045-1809150
Eyelash Rejuvenation Using Bimatoprost 0.03%: A Prospective Pilot Split-Face Study in Indian Population
Abstract
Background
Ophthalmic bimatoprost has been used worldwide for treatment of glaucoma, and enhanced eyelash growth has been reported with such use. Dermal application of prevalent bimatoprost preparations for eyelash enhancement has been reported with adverse effects.
Objective
This article assesses if revised formulation (Trulush) of bimatoprost 0.03% provides effective as well as safe eyelash enhancement in Indian population.
Materials and Methods
Prospective split-face study was conducted for 12 weeks in willing subjects for their eyelash rejuvenation. Subjects completed the pre- and post-study questionnaires for subjective evaluation. Bimatoprost (Trulush) was applied on the upper eyelid margin once a day. Adverse events were also assessed. Objective evaluation was done using available digital scale and pre- and post-study photographs at 12 weeks.
Results
All Subjects reported improvement in length, darkness, and density. Objective assessment corresponded with the subjective assessments. No significant adverse effects were reported by the subjects.
Conclusion
Bimatoprost 0.03%, in the available formulation (Trulush), is found to be effective for topical application and eyelash rejuvenation by their increase in length, darkness, and density. There are no significant side effects.
Publikationsverlauf
Artikel online veröffentlicht:
19. Mai 2025
© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Yoelin S, Walt JG, Earl M. Safety, effectiveness, and subjective experience with topical bimatoprost 0.03% for eyelash growth. Dermatol Surg 2010; 36 (05) 638-649
- 2 Wirta D, Pariser DM, Yoelin SG. et al. Bimatoprost 0.03% for the treatment of eyelash hypotrichosis: a pooled safety analysis of six randomized, double-masked clinical trials. J Clin Aesthet Dermatol 2015; 8 (07) 17-29
- 3 Easthope SE, Perry CM. Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension. Drugs Aging 2002; 19 (03) 231-248
- 4 Woodward JA, Haggerty CJ, Stinnett SS, Williams ZY. Bimatoprost 0.03% gel for cosmetic eyelash growth and enhancement. J Cosmet Dermatol 2010; 9 (02) 96-102
- 5 Dang J, Cole JC, Burgess SM, Yang M, Daniels SR, Walt JG. Development and validation of the eyelash satisfaction questionnaire. Aesthet Surg J 2016; 36 (02) 221-228
- 6 Smith S, Fagien S, Whitcup SM. et al. Eyelash growth in subjects treated with bimatoprost: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study. J Am Acad Dermatol 2012; 66 (05) 801-806
- 7 Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol 1997; 124 (04) 544-547
- 8 Harii K, Arase S, Tsuboi R, Weng E, Daniels S, VanDenburgh A. Bimatoprost for eyelash growth in Japanese subjects: two multicenter controlled studies. [published correction appears in Aesthetic Plast Surg. 2014 Oct;38(5):1071–2] Aesthetic Plast Surg 2014; 38 (02) 451-460
- 9 Wester ST, Lee WW, Shi W. Eyelash growth from application of bimatoprost in gel suspension to the base of the eyelashes. Ophthalmology 2010; 117 (05) 1024-1031